Latest Breaking News On - Results expected first half - Page 1 : comparemela.com

Study Designed to Evaluate Whether T-Guard is Superior to Ruxolitinib in Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host.

United statesFrance generalJohn levineGabrielle meyersYpke van oosterhoutSam martin carrie mckimMehdi hamadaniProfessor of the department hematologyNational cancer instituteCore transplant centers consortiaMarrow transplant researchInternational bloodOregon healthClinical researchBlood instituteSinai school of medicine